Sprint Bioscience Full Year 2023 Earnings: kr0.006 loss per share (vs kr1.43 loss in FY 2022)
Sprint Bioscience (STO:SPRINT) Full Year 2023 Results
Key Financial Results
- Revenue: kr54.3m (up by kr54.2m from FY 2022).
- Net loss: kr438.0k (loss narrowed by 99% from FY 2022).
- kr0.006 loss per share (improved from kr1.43 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Sprint Bioscience Earnings Insights
Looking ahead, revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Biotechs industry in Sweden.
Performance of the Swedish Biotechs industry.
The company's shares are up 2.9% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 2 warning signs for Sprint Bioscience you should know about.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:SPRINT
Sprint Bioscience
A pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden.
Flawless balance sheet and good value.